A new test to measure a specific protein modification linked to aging and disease.
An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts
This study is working on a quick and affordable test to measure a marker linked to aging and certain diseases, making it easier for doctors to keep track of conditions related to sugar levels in the body, just like the diabetes test many people know.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Revel Pharmaceuticals INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project ID | NIH-10914230 on NIH RePORTER |
What this research studies
This research focuses on developing a fast and cost-effective enzyme-based assay to measure Nε-carboxyethyl-lysine (CEL), a marker associated with aging and various diseases. The current methods for detecting CEL are slow and expensive, making them inaccessible for routine clinical use. By utilizing a newly discovered enzyme that oxidizes CEL, the researchers aim to create a simple test that can be performed quickly and at a lower cost, similar to the HbA1c test for diabetes. This advancement could facilitate better monitoring of glycation-related conditions and improve patient care.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing aging-related conditions or diseases associated with glycation and oxidative stress.
Not a fit: Patients who do not have aging-related conditions or diseases linked to glycation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more accessible and affordable way to monitor aging and disease-related protein modifications, leading to better patient outcomes.
How similar studies have performed: Similar approaches have shown promise in other areas of biomarker detection, indicating potential for success in this novel application.
Where this research is happening
San Francisco, UNITED STATES
- Revel Pharmaceuticals INC. — San Francisco, United States (Active)
Researchers
- Principal investigator: Cravens, Aaron — Revel Pharmaceuticals INC.
- Study coordinator: Cravens, Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.